QIAGEN NV (QIA)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 45.05 |
|---|---|
| 52-week range | 27.56 – 47.60 |
| Return, 1 month / 3 months | +17.0% / +23.2% |
| Return, 1 year / 3 years | +7.6% / +28.6% |
| Trend | Uptrend |
| RSI (14) | 81 |
| Volatility (1 year) | 32.8% |
| Worst drawdown (1 year) | -39.4% |
| Average daily value traded | 30.47M EUR |
| Dividend yield | 5.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
QIAGEN is a life-sciences and diagnostics company that supplies sample-preparation kits, assays and laboratory instruments used to isolate and analyse genetic material. Its products serve research laboratories, hospitals, clinical testing labs and pharmaceutical companies, supporting work in molecular diagnostics, applied testing and genomics. The company is based in the Netherlands and operates internationally, providing consumables and automated systems that help customers prepare samples and run molecular tests.
The shares are listed on the XETRA Stock Exchange in Germany under the code QIA, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
QIAGEN NV (QIA) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 45.05 on 23 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a strong price profile), ranking 99 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.6% and over the last three months it rose 23.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 23.5% | ||
| From 52-week high | -3.0% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 23.2% | ||
| 6-month return | 39.7% | ||
| 12-month return, skipping the last month | -8.0% | ||
| Stability (higher is calmer) | 47 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.4% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 30.47M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 47 · Weak | Dividend is small or irregular. | |
| Dividend yield | 5.2% | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +9.8% |
|---|---|
| 1 month | +17.0% |
| 3 months | +23.2% |
| 6 months | +39.7% |
| 1 year | +7.6% |
| 3 years | +28.6% |
| 5 years | −1.5% |
Signals
| 50-day / 200-day average | 38.87 / 36.47 |
|---|---|
| Golden / death cross (60 days) | Golden, 33 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.20 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Jul 2026 | EUR 0.3113 |
| 8 Jan 2026 | EUR 2.0370 |
| 2 Jul 2025 | EUR 0.2224 |
| 29 Jan 2025 | EUR 1.1208 |
| 30 Jan 2024 | EUR 1.1822 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.